NFKB1 and inflammatory breast carcinoma: The upregulated expression of RIPK2 and activation of inflammatory mediators, especially the hyperactivated stage of NF-κB signaling in IBC makes it more reasonable for synergy between RIPK2 inhibitors and ICIs.